Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $14.00

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its price target boosted by Maxim Group from $12.00 to $14.00 in a report published on Friday, Marketbeat.com reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Sensus Healthcare in a research report on Monday, August 12th.

Sensus Healthcare Trading Up 4.3 %

SRTS traded up $0.31 during trading on Friday, reaching $7.60. The stock had a trading volume of 772,333 shares, compared to its average volume of 275,613. The company has a market capitalization of $124.56 million, a price-to-earnings ratio of 18.78 and a beta of 1.04. The stock's 50 day moving average is $6.32 and its two-hundred day moving average is $5.91. Sensus Healthcare has a one year low of $2.02 and a one year high of $8.29.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors have recently modified their holdings of SRTS. Renaissance Technologies LLC raised its position in shares of Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company's stock worth $2,087,000 after purchasing an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company's stock worth $888,000 after buying an additional 93,511 shares in the last quarter. Sachetta LLC grew its holdings in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company's stock valued at $631,000 after buying an additional 13,544 shares during the last quarter. Marshall Wace LLP increased its position in shares of Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company's stock valued at $412,000 after acquiring an additional 46,732 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company's stock valued at $239,000 after acquiring an additional 38,474 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.